[The availability of only one statin is inadequate].
When looking at the history of the prescription of a new class of drugs e.g. the statin, it is clear that for optimal use with regard to efficacy, areas of indication and safety, the continuous development of new compounds within this class was very advantageous. Competition between compounds is essential for providing best patient care. Thus the availability of only one statin was and continues to be inadequate for this purpose.